αPD1-MSLN-CAR T cells

BIOLOGICAL4 trials

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shanghai Cell Therapy Group Co.,Ltd, Shanghai Mengchao Cancer Hospital

Conditions

Advanced Solid TumorColorectal CancerMesotheliomaNon-small-cell Lung CancerOvarian CancerSolid Tumor

Early Phase 1

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyMesothelioma, Non-small-cell Lung Cancer

Start: 2020-05-13End: 2022-12-31Target: 10Updated: 2020-07-28

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Shanghai Cell Therapy Group Co.,LtdColorectal Cancer, Ovarian Cancer

Start: 2020-03-26End: 2022-06-30Target: 10Updated: 2020-08-07

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Shanghai Mengchao Cancer HospitalSolid Tumor

Start: 2020-10-30End: 2023-08-31Target: 21Updated: 2022-10-26

Phase 1

Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors

Shanghai Cell Therapy Group Co.,LtdAdvanced Solid Tumor

Start: 2023-09-30End: 2025-09-30Target: 42Updated: 2023-07-14

Related Papers

Abstract CT134: Non-viral mesothelin-targeted CAR-T cells armored with IFNg-induced secretion of PD-1 nanobody in treatment of malignant mesothelioma in phase I clinical trial

Cancer Research2023-04-147 citations